HLTH vs. AXDX, TLIS, OMIC, PRPO, TBIO, RPID, PRE, BNGO, PAVM, and MEIP
Should you be buying Cue Health stock or one of its competitors? The main competitors of Cue Health include Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Singular Genomics Systems (OMIC), Precipio (PRPO), Telesis Bio (TBIO), Rapid Micro Biosystems (RPID), Prenetics Global (PRE), Bionano Genomics (BNGO), PAVmed (PAVM), and MEI Pharma (MEIP). These companies are all part of the "medical" sector.
Cue Health (NASDAQ:HLTH) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
Accelerate Diagnostics has a consensus target price of $1.00, suggesting a potential upside of 13.80%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than Cue Health.
Accelerate Diagnostics has a net margin of -452.28% compared to Cue Health's net margin of -526.48%. Accelerate Diagnostics' return on equity of 0.00% beat Cue Health's return on equity.
45.5% of Cue Health shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 12.5% of Cue Health shares are owned by company insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.33% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Accelerate Diagnostics has lower revenue, but higher earnings than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cue Health had 1 more articles in the media than Accelerate Diagnostics. MarketBeat recorded 3 mentions for Cue Health and 2 mentions for Accelerate Diagnostics. Accelerate Diagnostics' average media sentiment score of 0.34 beat Cue Health's score of -0.16 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.
Cue Health has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Summary
Accelerate Diagnostics beats Cue Health on 11 of the 18 factors compared between the two stocks.
Get Cue Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Health Competitors List
Related Companies and Tools
